Alectinib

An anaplastic lymphoma (tyrosine) kinase inhibitor.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

1
Supporting references
0
Contradictory references
2
AI-suggested references
0
Clinical trials

General information

Alectinib on PubChem


Marketed as

ALECENSA; ALECENSARO

 

Structure image - Alectinib

CCC1=CC2=C(C=C1N3CCC(CC3)N4CCOCC4)C(C5=C(C2=O)C6=C(N5)C=C(C=C6)C#N)(C)C


Supporting references

Link Tested on Impact factor Notes Publication date
Identification and characterization of novel RdRp and Nsp15 inhibitors for SARS-COV2 using computational approach
RdRpol nsp15 Small molecule In silico
in silico 3.22

Predicted to inhibit the SARS-CoV-2 RNA-dependent RNA polymerase and nsp15 protein.

Nov/05/2020

AI-suggested references